Polivy's Primary Approval
Polivy (polatuzumab vedotin-piiq), an antibody-drug conjugate from Genentech, gained FDA accelerated approval in 2019 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab. Full approval followed in 2023 based on the GO29365 trial, which showed improved progression-free survival (PFS) versus bendamustine-rituximab alone—12.4 months median PFS for Polivy combo versus 4.7 months.[1][2]
Key Trial Data on Effectiveness
The pivotal phase 2 GO29365 study enrolled 80 patients with transplant-ineligible R/R DLBCL after at least one prior CD20-targeted therapy. Polivy plus BR achieved a 40% complete response (CR) rate and 45% overall response rate (ORR), with median overall survival (OS) of 12.4 months. Effectiveness held across subgroups like primary refractory disease and those failing CAR-T.[1][3]
Ongoing phase 3 trials like POLARIX (NCT03274492) tested Polivy-R-CHP frontline in previously untreated DLBCL, meeting its PFS endpoint in 2022 and supporting label expansion.[2]
Other Lymphoma Subtypes Tested
Polivy showed activity in earlier studies:
- Follicular lymphoma: Phase 2 data (ROMULUS trial) reported 59% ORR in R/R patients after ≥2 prior therapies.[4]
- Other B-cell lymphomas: Exploratory effectiveness in mantle cell, marginal zone, and transformed follicular lymphomas, with ORR around 50% in small cohorts, though not approved.[1]
No approvals beyond DLBCL.
Ongoing Trials and Potential Expansions
Phase 3 trials explore Polivy in:
- Frontline DLBCL (POLARIX: positive PFS data).
- R/R DLBCL post-CAR-T (e.g., NCT04182204).
- High-grade B-cell lymphoma.
No data supports solid tumors or non-lymphoma cancers; development focuses on B-cell malignancies.[2][5]
Limitations and Patient Outcomes
Effectiveness drops in heavily pretreated patients; common adverse events include neutropenia (42%), thrombocytopenia (29%), and peripheral neuropathy (40%), limiting use in frail patients. Real-world studies confirm trial PFS benefits but note higher toxicity.[3][6]
Sources
[1]: Polivy Prescribing Information (FDA)
[2]: Genentech Press Release on Full Approval
[3]: NEJM: GO29365 Trial Results
[4]: Blood Advances: ROMULUS Trial
[5]: ClinicalTrials.gov Search for Polivy
[6]: DrugPatentWatch.com - Polivy Patent Status